EGE. A. Gaisina

E. A. Gaisina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Gaisina has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world outcomes of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: A retrospective cohort study

    by I. A. Filippov, E. A. Gaisina, M. S. Shvedsky, L. A. Bakhova, G. D. Salikova, E. A. Avsievich, E. G. Melkova, R. Е. Alieva, I. A. Inurkaeva, N. I. Marts, et al.

    Introduction . Hepatocellular carcinoma (HCC) ranks sixth in morbidity and third in mortality among oncological diseases in the world. The combination of atezolizumab (a PD-L1 inhibitor) and bevacizumab (anti-VEGF) is the standard of first-line systemic therapy for unresectable HCC based on the results of the randomized IMbrave150 trial. Data on the use of this scheme in real clinical practice in the Russian population remains limited. Aim. To assess the efficacy and safety of atezolizumab plus bevacizumab in HCC patients in a real-world single-center setting. Materials and methods. This retrospective cohort study included 15 patients with histologically or clinically confirmed HCC receiving atezolizumab 1200 mg + bevacizumab 15 mg/kg IV every 3 weeks at Medical Center Medical City (Tyumen) from 2021 to 2025. Results . The median age of the patients included in the study was 49.6 years (range 27.6–73.1 years; mean 51.9 ± 12.3 years). Male patients prevailed – 10 (66.7%), 5 (33.3%) women. Stage BCLC C – 66.7% (10/15), BCLC B – 5/15 (33.3%). Viral hepatitis C was detected in 46.7% (7/15) of patients, hepatitis B in 13.3% (2/15), and the viral etiology of HCC was not established in 40.0% (6/15) of patients. The medians of PFS and OS were not reached, and the median follow-up was 16 months. The average number of courses conducted is 9 (range 2–21). The ORR was 37.7%. Adverse events were reported in 26.7% (4/15) of patients; the most significant were grade 1–2 autoimmune hepatitis, thrombocytopenia, and ischemic stroke. Conclusion . Real-world data confirm the efficacy and manageable toxicity of atezolizumab plus bevacizumab in HCC.

  • Open Access

    Clinical and Diagnostic Features and Treatment Outcomes of Locally Advanced Medullary Thyroid Carcinoma in the Tyumen Region, Russia

    by M. I. Sokolova, V. I. Pavlova, E. A. Gaisina

    Introduction. Medullary thyroid carcinoma (MTC) is a rare and aggressive malignancy, accounting for 2–5% of all thyroid cancers. Aim. This study examined the epidemiological profile of MTC in the Tyumen Region (Russia) and evaluated the effectiveness and tolerability of multikinase inhibitors (MKIs) in MTC therapy. Materials and methods. The analysis included 69 patients with MTC treated between 2017 and 2025. Patient age ranged from 39 to 78 years (median 57). Sonographic characteristics of thyroid nodules were classified according to the EU-TIRADS. Cytological evaluation of fine-needle aspiration samples followed the Bethesda Thyroid Classification (2009, 2017, 2023). Survival outcomes were calculated using the Kaplan–Meier method. Serum calcitonin (CT) and carcinoembryonic antigen (CEA) levels were measured by electrochemiluminescence. RET mutation testing was performed on blood samples and, in one case, on surgical tissue. Results . Between 2017 and 2025, peak MTC incidence in the Tyumen Region occurred in 2021 and 2024, reaching 0.65 and 0.74 per 100,000 population, respectively. During cabozantinib therapy, mean survival was 19.30 months (95% CI 14.45–21.39), with a median of 17.01 months. For vandetanib in first-line therapy, mean survival was 18 months (95% CI 12.57–23.59), with a median of 14.00 months (95% CI 12.46–20.55). The objective response rate was 29.4% with vandetanib and 36.8% with cabozantinib. The most frequent adverse events were arterial hypertension with vandetanib, palmar-plantar erythrodysesthesia with cabozantinib, and toxic hepatitis with selpercatinib. Discussion. This retrospective analysis demonstrates the effectiveness and safety of MKIs in routine clinical practice. Cabozantinib showed superior survival outcomes and objective response rates compared to vandetanib. The observed adverse events were expected and manageable. The findings are consistent with published clinical evidence. Conclusion . Given the aggressive nature of MTC, continuous monitoring of disease progression is essential. In cases of progression, MKI therapy should be considered, with careful evaluation of potential toxicity in relation to individual treatment goals.

  • Open Access

    Predictive model for assessing probability of breast cancer biological subtype change during treatment

    by M. S. Shvedskiy, Шведский М. С., R. I. Tamrazov, Тамразов Р. И., E. A. Gaysina, Гайсина Е. А.

    Background. Breast cancer demonstrates significant biological heterogeneity, which determines disease prognosis and the choice of systemic therapy. In clinical practice, the molecular subtype of the tumor is traditionally considered a relatively stable characteristic; however, recent data indicate the possibility of its change during the course of treatment. Investigation of patterns of tumor biological transformation represents an important area of personalized oncology, as such changes may influence the efficacy and appropriateness of the administered therapy. Aim. To develop a multiparametric prognostic model integrating histological, immunohistochemical, and clinical data for predicting changes in the molecular subtype of breast cancer. Materials and methods. The retrospective study included 261 patients with histologically verified invasive breast cancer treated between 2006 and 2025 at the "Medical City" Multidisciplinary Clinical Medical Center (Tyumen). Depending on the presence or absence of a change in the tumor molecular subtype, defined as a change in the immunohistochemical subtype between sequential examinations, patients were divided into two groups: group 1 – patients with confirmed subtype change; group 2 – patients without subtype change. Results. The developed prognostic model demonstrated AUC (area under curve, 0.779 (95 % confidence interval 0.71–0.82) with specificity of 85 % and sensitivity of 51 % at the standard cut-off threshold ( 0.5). With optimized threshold of p = 0.32, sensitivity of the model reached 72.4 %, specificity – 71.3 %. Internal bootstrap validation (1000 repetitions) confirmed stability of the model: AUC 0.79 (95 % confidence interval 0.72–0.86). To improve predictive accuracy, additional machine learning methods were applied (Random Forest: AUC 0.79, F1 0.77; LASSO: AUC 0.81, F1 0.78), which confirmed robustness of the identified predictors and consistency of prognostic estimates. Conclusion. Changes in the molecular subtype of breast cancer are a predictable event. The developed model enables identification of patients at high risk of tumor biological transformation, which may help optimize dynamic monitoring and ensure timely adjustment of therapeutic strategies.